207 research outputs found
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Get PDFA Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer"
Get PDFCorrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
Get PDFIn-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study
Get PDFOral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer
Get PDFENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design
Get PDFPARP1 and immune checkpoint inhibition after chemotherapy induction in leiomyosarcoma: a model to unleash immunoresponse
Get PDFLong-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
Get PDFOvercoming endocrine resistance in metastatic breast cancer: Current evidence and future directions
Get PDF
- …
